Abstract: A nanoparticle for detecting or treating a tumor is provided. The nanoparticle includes a plurality of polymer backbones and at least one first detectable substance, of which each of the polymer backbones includes a hydrophobic region, a hydrophilic region and a chelating region, and the first detectable substance is bound to the chelating region of the polymer backbone. The hydrophobic regions of the polymer backbones form a core block, and the hydrophilic regions of the polymer backbones form a shell block surrounding the core block. A method for detecting or treating a tumor using the nanoparticle is also provided.

Abstract: [Problem] To provide a novel polymer derivative of a cytidine metabolic antagonist which allows release of a medicament irrespective of enzymes of the living body and is expected to have high therapeutic effects.

Abstract: Vinylamine-containing polymers are disclosed where the amine groups are substituted with (1) cationic functional groups, (2) anionic functional groups, (3) hydrophobic functional groups, (4) hydrophilic functional groups, (5) functional groups that impart amphoteric characteristics to the polymers, or (6) combinations thereof. Also disclosed are processes for preparing such polymers, as well as compositions comprising such polymers. Among other applications, these polymers can be used in papermaking applications as dry strength additives, wet strength additives, retention aids, drainage aids, and pitch and stickies control agents.

Abstract: A method capable of effectively improving a rejection of a reverse osmosis membrane without remarkably reducing a permeation flux, even if the membrane is seriously degraded. An aqueous solution containing a first organic compound having a molecular weight of less than 200, a second organic compound having a molecular weight of 200 to less than 500, and a third organic compound having a molecular weight of 500 or more is passed through the reverse osmosis membrane. The first organic compound is preferably an amino acid or an amino acid derivative. The total concentration of the first organic compound and the second organic compound and the concentration of the third organic compound are each preferably 1 to 500 mg/L.

Abstract: Biomimetic adhesive compositions can be used in various aspects of subterranean treatment operations. Methods for treating a subterranean formation can comprise: providing an adhesive composition that comprises a first polymer comprising a plurality of monomers that comprise a phenolic moiety, a biopolymer that is crosslinkable with the first polymer, a crosslinking agent, and an oxidizing agent; introducing the adhesive composition into a subterranean formation; and forming a coacervate-bound surface in the subterranean formation by crosslinking the first polymer.

Abstract: The invention provides molecule-responsive gel particles which change in size in response to specific molecules and a method of production of the same. A polymer gel particle with a crosslinked structure has fixed thereto a plurality of clathrate compound-forming host molecules. Two or more of the plurality of host molecules clathrate different atomic groups in a target molecule so that the two or more host molecules and the target molecule can form a crosslink in the molecule-responsive gel particle.

Abstract: Provided are a use of chemically-crosslinkable, poly(organophosphazene)s for biomaterials, chemically-crosslinkable poly(organophosphazene)s with a physiologically active substance covalently-bonded thereto, a use thereof for biomaterials, and a process for preparing the same. The chemical crosslinkings can be made by UV irradiation, and/or a crosslinker, and/or an additive, and/or an enzyme, and/or a mixing of at least one polymer.

Abstract: A new class of poly(beta-amino alcohols) (PBAAs) has been prepared using combinatorial polymerization. The inventive PBAAs may be used in biotechnology and biomedical applications as coatings (such as coatings of films or multilayer films for medical devices or implants), additives, materials, excipients, non-biofouling agents, micropatterning agents, and cellular encapsulation agents. When used as surface coatings, these PBAAs elicited different levels of inflammation, both in vitro and in vivo, depending on their chemical structures. The large chemical diversity of this class of materials allowed us to identify polymer coatings that inhibit macrophage activation in vitro. Furthermore, these coatings reduce the recruitment of inflammatory cells, and reduce fibrosis, following the subcutaneous implantation of carboxylated polystyrene microparticles. These polymers may be used to form polyelectrolyte complex capsules for cell encapsulation.

Abstract: An object of the present invention is to provide a glucosamine-containing glucan, a modified product and a conjugate thereof. The glucosamine-containing glucan of the present invention is a glucosamine-containing glucan wherein the glucan has a plurality of non-reducing ends and at least one glucosamine residue is bound via an ?-1,4-bond to each of two or more non-reducing ends of the branched ?-1,4-glucan, but no glucosamine residue is present at a position other than the non-reducing ends of the branched ?-1,4-glucan, wherein the degree of polymerization of the glucan is 15 or more and 4×105 or less. The glucosamine-containing glucan of the present invention can be provided by allowing an ?-glucan phosphorylase to act on an aqueous solution comprising a branched ?-1,4-glucan and glucosamine-1-phosphate.

Abstract: Novel hyaluronic acid-containing biopolymers are provided which exhibit increased hydrophilicity and reduced protein adsorption. In one aspect, the biopolymer incorporates hyaluronic acid modified to include a linking agent in a molar excess sufficient to yield a degree of HA modification in a range of about 1-5. In another aspect, the biopolymer incorporates unmodified hyaluronic acid.

Abstract: Provided are a polyrotaxane capable of using an aqueous solvent in a fabricating process although it has hydrophobicity, an aqueous composition having the polyrotaxane, a crosslinked body comprising the polyrotaxane, etc. The polyrotaxane comprises blocking groups located at both ends of a pseudo-polyrotaxane having cyclic molecules and a linear molecule which pierces the cavities of the cyclic molecules in a skewered manner to form a clathrate therewith so as not to detach the cyclic molecules, wherein the cyclic molecules have a group represented by Formula I, a group represented by Formula II and a group represented by Formula III. Incidentally, M represents, for example, a group derived from ring-opening polymerization of ?-caprolactone or the like, A represents a hydroxy group or the like, B represents a —COOH group or the like, and C represents A and/or B: -M-A??Formula I; -M-B??Formula II; and —C??Formula III.

Abstract: A modified compound that has at least one further functional group, in particular a bio- or macromolecule, comprising at least one x-fold (x?1) chemoselectively incorporated phosphoramidate group of general formula (I), NPO(OR1)(OR1?), and/or at least one x-fold (x?1) chemoselectively incorporated phosphonamide group of general formula (Ia), NPO(R1)(OR1?). R1 and R1? is selected from the group containing glycerol, polyglycerol, PEG polymers of the general empirical formula C2nH4n+2On+1 with n?1, Cn-alkyl chains with n?1; functionalized Cn-alkyl chains with n?1, aryls, heteroaryl, silyl, lipids, fluorophores, saccharides, peptides, crown ethers, or a linker, which links the aforementioned groups. R1 and R1? can be identical to or different from one another.

Abstract: The present invention provides membrane lytic poly(amido amine) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.

Abstract: The present invention relates to a water-soluble polymer complex that includes a water-soluble block copolymer and a magnetic nanoparticle, wherein the water-soluble polymer complex has a nonzero net magnetic moment in the absence of an applied magnetic field at ambient temperatures. The water-soluble block copolymer is preferably a diblock or triblock copolymer and the magnetic nanoparticle is preferably a ferrimagnetic or ferromagnetic nanoparticle. The water-soluble complexes may be derivatized with reactive groups and conjugated to biomolecules. Exemplary water-soluble polymer complexes covered under the scope of the invention include PEG112-b-PAA40 modified CoFe2O4; NH2-PEG112-b-PAA40 modified CoFe2O4; PNIPAM68-b-PAA28 modified CoFe2O4; and mPEG-b-PCL-b-PAA modified CoFe2O4.

Abstract: The invention provides a method comprising the steps of providing a poly(ethylene glycol) having one terminal hydroxyl group; reacting the terminal hydroxyl group of the poly(ethylene glycol) with di(1-benzotriazolyl)carbonate to form a 1-benzotriazolylcarbonate ester of the poly(ethylene glycol); reacting the 1-benzotriazolylcarbonate ester of the poly(ethylene glycol) with an amino acid to form an amino acid derivative; and reacting the amino acid derivative with a biologically active agent under conditions to form a polymer-active agent conjugate.

Abstract: A structured drug system that is useful for delivering a drug payload to a specific tissue or cell type is disclosed. The system is based on purified polymalic acid. This polymer isolated from natural sources is biocompatible, biodegradable and of very low toxicity. The polymer is extremely water soluble and contains a large number of free carboxyl groups which can used to attach a number of different active molecules. In the examples disclosed N-hydroxysuccinimide esters of the carboxyl groups are used to attach such molecules. The active molecules include monoclonal antibodies to promote specific cellular uptake and specific pro-drugs such as antisense nucleic acids designed to modify the cellular metabolism of a target cell. The pro-drugs are advantageously linked by a somewhat labile bond so that they will be released under specific conditions. In addition, the system contains amide-linked valine to encourage membrane disruption under lysosomal conditions.

Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

Abstract: A composition comprises a polyvinylchloride homopolymer, a biodegradable plasticizer and either a swelling agent or a carbohydrate coupled to the polyvinylchloride homopolymer or a combination thereof. The composition may further comprise a blowing agent. A coated fabric comprises a textile substrate and a biodegradable coating at least partially coating the textile substrate, wherein the biodegradable coating degrades at least 60% after 28 days under the ASTM D584 standard. A method of making a biodegradable coating comprises providing a polymer and blending a biodegradable plasticizer with the polymer to form a blend. A method of making a coated textile comprises providing a textile and a composition comprising a polymer, a biodegradable plasticizer, and at least one other component; applying the composition to the textile; and curing the composition, thereby making a coated textile.

Abstract: The present invention provides an efficient delivery system for a nucleic acid, more specifically, a cationic poly(amino acid) that has a side chain having a plurality of different amine functional groups in a moiety including a cationic group and that has a hydrophobic group introduced into part of the side chain, and a polyion complex (PIC) of the poly(amino acid) and an oligo- or polynucleotide.

Abstract: The present invention provides poly(amide) polymers, polyconjugates, compositions and methods for the delivery of oligonucleotides for therapeutic purposes.

Abstract: A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell.

Abstract: Provided is a slush molding material which exhibits excellent low-temperature meltability and heat resistance and which can yield a molded product having excellent tensile strength and elongation. The present invention is urethane resin particles (D1) comprising a urethane or urethane-urea resin (U1) that has residues (j) bonded thereto covalently, said residues (j) being residues derived from an at least trivalent aromatic polycarboxylic acid by removing hydroxyl groups, or urethane resin particles (D2) comprising a urethane resin composition (S2) which comprises both a urethane or urethane-urea resin (U2) and a compound (E) that has a residue (j) derived from an at least trivalent aromatic polycarboxylic acid by removing hydroxyl groups, said compound (E) being represented by general formula (1), wherein the residues (j) are linked respectively to urethane or urea groups (u) of the resin (U1) or (U2) by hydrogen bonds.

Abstract: Disclosed are highly resilient and cohesive gels formed by the cross-linking of hyaluronan or hylan, their salts or derivatives thereof, using divinyl sulfone (DVS) as the cross-linking agent. Also disclosed are viscoelastic fluids containing alkylsulfone groups covalently attached to the backbone of the polymer, formed by the mono-functionalization of the cross-linking monomer DVS with hyaluronan and/or hylan. Mechanical properties such as values of hardness and cohesiveness are specified by the rheological properties of the gels. Also disclosed are methods for the preparation of such products. They have use in many applications as injectable and/or implantable devices and as drug delivery systems.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: A method of conjugating a substrate includes exchanging a counter ion associated with a biomolecule with a lipophilic counter ion to form a biomolecule complex, dispersing the biomolecule complex in a nonaqueous solvent, and coupling the biomolecule complex to a substrate in the presence of the nonaqueous solvent.

Abstract: Provided are compositions for controlled release of biomolecules, which comprise conjugates of polymers and biomolecules conjugated through non-covalent interactions. Also provided are methods for controlled release of biomolecules and their use in biochips.

Abstract: Thermoplastic polymer compositions, films, continues, closures, laminates can comprise a modified vinyl polymer said modified polymer having a moiety comprising a cyclodextrin compound. The cyclodextrin compound, locked into the polymer structure, can absorb impurities, permeants, or other undesirable volatile materials. The cooperation between the cyclodextrin grafted onto the thermoplastic polymer and the polymer structure can provide barrier properties to a film, web or other polymer structure. A permeant or a contaminant can be complexed or trapped within the polymer and held within the film or Web preventing the permeant or contaminant from passing into the interior of a container or enclosure.

Abstract: A new copolymer synthesized from a glycosaminoglycan (GAG) such as hyaluronan/hyaluronic acid (HA), chondroitin sulfates, derma tan sulfates, keratan sulfates, heparan sulfate, and heparin, and an anhydride functionalized hydrophobic polymer, i.e., any polyolefin which has been ‘functionalized’ (grafted onto the backbone or incorporated into the backbone) with anhydride functional groups, such as maleic anhydride-graft-polyethylene, (or, maleated polyethylene), maleic anhydride-graft-polystyrene, maleic anhydride-graft-polypropylene, etc. The functionalized polyolefin may be a polyolefin backbone to which the anhydride functional groups have been grafted, or otherwise incorporated with the backbone. Also, a unique synthesis technique combines a modified GAG with a graft polyolefin, resulting in a unique copolymer with its constituents by-and-large covalently bound to each other.

Abstract: A PAA nanoparticle containing a covalently linked fluorescent dye and a post-loaded tetrapyrrolic photosensitizer.

Abstract: Described herein are gold particles that can be used to reduce tumor proliferation and treat cancer. In certain aspects, the gold particles can be modified in order to enhance selectivity and uptake of the particles by cancer cells. In certain aspects, the modified gold particles have a targeting group attached to the particle via a linker. The gold particles described herein can be used in combination with other anti-cancer agents in order to enhance overall cancer treatment. Methods for making and using the gold particles are also described herein.

Abstract: Provided herein are immunoreactive peptides which can selectively bind Ehrlichia-specific anti-p120 or anti-p140 antibodies. Methods and kits utilizing the immunoreactive peptides are also provided. The immunoreactive peptides may be utilized, e.g., for determining whether or not a subject is infected with Ehrlichia chaffeensis or Ehrlichia canis. In certain embodiments, the immunoreactive peptides may be utilized in an ELISA or lateral flow assay.

Abstract: Described herein are modified gelatins or the pharmaceutically-acceptable salts or esters thereof comprising at least one actinically crosslinkable group covalently bonded to gelatin. The modified gelatins are useful in producing composites that ultimately can be used to produce three-dimensional engineered biological constructs. The composites are the polymerization product between the modified gelatin and at least one actinically crosslinkable macromolecule. Methods for making the modified gelatins are also described herein.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: A process for producing carrier polymer particles comprising covering the surface of organic polymer particles having a particle diameter of 0.1 to 20 micrometers with a saccharide by chemically bonding the organic polymers and the saccharide.

Abstract: A method is provided for the preparation of a poly(amic acid) in which ring opening polymerization is employed to react the monomers ethylenediaminetetraacetic dianhydride and paraphenylenediamine in an aprotic solvent. The resulting poly(amic acid) composition is suitable as a biocompatible material, such as a biomedical implant, implant coating material, tissue scaffold material, controlled release drug delivery vehicle, and cellular growth substrate.

Abstract: Targeting of imaging probes specifically to diseased tissues such as cancer is attractive because it potentially allows the improvement of tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor:background ratio. To circumvent this, imaging probes may be conjugated to polymeric carriers to target solid tumors by either passive accumulation of macromolecules into tumor tissues due to the “enhanced permeability and retention” effect (EPR effect) or active targeting through the incorporation of cell-specific recognition ligands that mediate binding to cancer-specific antigens. This invention describes an innovative targeting strategy for the selective delivery of diagnostic agents into solid tumors by means of polymer-NIR fluorochrome conjugates modified with targeting ligands that bind to antigens or receptors that are uniquely expressed or over-expressed on the target cells relative to normal tissues.

Abstract: It is intended to provide a crosslinked polyrotaxane formed by crosslinking polyrotaxane molecules via chemical bonds which exhibits excellent optical properties in water or in an aqueous solution of sodium chloride; a compound having this crosslinked polyrotaxane; and a process for producing the same. The above object can be achieved by a crosslinked polyrotaxane having at least two polyrotaxane molecules, wherein linear molecules are included in a skewered-like state at the opening of cyclodextrin molecules and blocking groups are provided at both ends of the linear molecules, so as to prevent the cyclodextrin molecules from leaving, and cyclodextrin molecules in at least two polyrotaxane molecules being bonded to each other via chemical bond, characterized in that hydroxyl (—OH) groups in the cyclodextrin molecules are partly substituted with non-ionic groups.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: The present invention relates to articles made of a thermoformable resin comprising a biodegradable polymer having polybutylene succinate (PBS) via extrusion using an extruder which comprise: a biodegradable polymer having: (a) a Ts value of up to about 160° C. (e.g., in the range of from about 50° to about 150° C.); (b) a heat distortion index of up to about 150° C. (for example, up to about 120° C.); and (c) optionally, a Tm in the range of from about 70° to about 160° C. (e.g., in the range of from about 80° to about 150° C.). Thermoformed article such as a food or beverage cup, lid, cutlery item, foodservice item, molded tray, food storage container, etc provide the ability to resist deformation during higher temperature conditions that may occur during storage and distribution.

Abstract: The application provides a method of producing a comb polymer comprising the steps of: (a) Providing: (i) a plurality of monomers which are linear, branched or star-shaped, substituted or non-substituted, and have an olefinically unsaturated moiety, the olefinically unsaturated moiety being capable of undergoing addition polymerization; (ii) an initiator compound; the initiator compound comprising a homolytically cleavable bond. (iii) a catalyst capable of catalysing the polymerization of the monomer; and (b) Causing the catalyst to catalyse, in combination with the initiator, the polymerization of a plurality of the monomers to produce the comb polymer. Catalysts and polymers obtainable by the process are also provided. Preferably, the comb polymer is capable of binding proteins and may be produced from monomers which are alkoxy polyethers, such as poly(alkyleneglycol) or polytetrahydrofuran.

Abstract: Polymers comprising glucosamine (GlcN) are used to make medical devices. Examples include polyGlcN and carrier molecules containing multiple GlcN residues.

Abstract: Novel method and reagents for generating reversibly tagged saccharides, aldehydes, carboxyl acids, or orthoacetates useful in analytical and diagnostic applications are disclosed. Saccharides are coupled at the reducing end to tagging moieties comprising a reagent selected from a ortho-diaminobenzoic(DAB)-peptide, an aldo-imidazole or N-methylated aldo-imidazole, or an ortho-phenyldiamine (OPD) or substituted OPD. The tagged saccharide further comprising detectable or functional groups coupled to the tagging moiety are provided. Kits and reagents for chromatography and mass spectrometry are disclosed.

Abstract: The present invention relates to a temperature-sensitive carrier for carrying a physiologically active substance and a preparation method thereof. Specifically, the temperature-sensitive carrier according to the present invention comprises an amphiphilic biodegradable block copolymer containing polysaccharide or polysaccharide and succinic anhydride as a hydrophilic block and polylactide as a non-ionic block. A hydrophilic polymer-polylactide copolymer according to the present invention forms a stable complex with a physiologically active substance such as protein, polynucleotide and the like in vivo via ionic bonding and temperature-sensitive hydrophobic bonding. Therefore, a copolymer according to the present invention can facilitate in vivo delivery of a physiologically active substance and used as an in vivo drug delivery system.

Abstract: The present disclosure is directed, in part, to a curable composition, a method for augmenting a structure in a patient with a resorbable biocompatible polymer, and a biodegradable, resorbable implant comprising a biocompatible copolymer. An exemplary embodiment of the curable composition comprises (a) 60 wt. % to 95 wt. % of one or more vinyl ester monomers and/or vinylcarbonate monomers, wherein said one or more vinyl ester monomers and/or vinylcarbonate monomers are respectively selected from compounds of the general formulas (I) and (II) below: wherein n, m R1 and R2 have the meaning defined herein; (b) 0.1 to 40 wt. % of one or more multifunctional thiols; and (c) 0 to 10 wt. % of a biocompatible polymerization initiator.

Abstract: The present disclosure provides a polymer comprising a derivative of chitosan, wherein the derivative is zwitterionic, as well as methods of using the polymer. In addition, the present disclosure provides a nanoparticle structure comprising a derivative of chitosan and a dendrimer, as well as methods of utilizing the nanoparticle structure.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Polyester compositions and functionalized polyester compositions are provided along with methods of making the compositions as well as methods of using the compositions, for example as a tissue engineering bioscaffold and as a drug-delivery vehicle.

Abstract: The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.

Abstract: Provided are a method and kit for isolating a target cell by using particles comprising polymers having positive charge and negative charge and at least one antibody bound to polymers. The target cell in the biological sample may be efficiently isolated and detected by using a method and kit according to an exemplary embodiment.

Abstract: This invention belongs to the nanotechnology field, and discloses a nano drug delivery system with polyethyleneglycol-poly(lactic-co-glycolic acid)-poly-L-lysine (PEG-PLGA-PLL) polymer as the skeleton. The carrier can have the function of passive targeting through control of the carrier particle size. The polymer skeleton is modified through introducing side chains and specific targeting groups, so as to adjust and improve the carrier performance, and enable the carrier to have the function of active targeting. Such carrier material also has the functions of transporting active substances, tumor treatment and diagnosis, ultrasonic contrast, reversing or reducing drug resistance and so on.